Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
forimtamig + daratumumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Forimtamig + daratumumab is an investigational combination therapy for the treatment of relapsed or refractory multiple myeloma. **Forimtamig** is a novel T-cell bispecific monoclonal antibody that simultaneously targets **GPRC5D** on malignant plasma cells and **CD3** on T cells, inducing immune-mediated destruction of cancerous plasma cells. It features a silent Fc region to reduce toxicity and increase half-life. **Daratumumab** is an anti-CD38 monoclonal antibody that binds CD38 on multiple myeloma cells and induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. This combination is being evaluated for synergistic activity, seeking to improve response rates and durability of response in patients with highly refractory or relapsed disease.
- Other names
- forimtamig + Darzalex
02
Targets
CD38 (Cluster of Differentiation 38)CD3 (T-cell surface glycoprotein CD3)GPRC5D
Beyond the preview
Go deeper on forimtamig + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on forimtamig + daratumumab.